KEX Valuation
Kirby Corp
$
110.250
- Overview
- Forecast
- Valuation
KEX Relative Valuation
KEX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, KEX is overvalued; if below, it's undervalued.
Historical Valuation
No Data
Competitors Valuation Multiple
The average P/S ratio for KEX's competitors is 3.52, providing a benchmark for relative valuation. Kirby Corp Corp (KEX) exhibits a P/S ratio of 1.78, which is -49.45% above the industry average. Given its robust revenue growth of -2.77%, this premium appears unsustainable.
People Also Watch
BBIO
BridgeBio Pharma Inc
33.840
USD
+0.30%
BMI
Badger Meter Inc
244.970
USD
+0.32%
LNTH
Lantheus Holdings Inc
81.240
USD
+1.83%
MDGL
Madrigal Pharmaceuticals Inc
290.960
USD
-0.29%
GNTX
Gentex Corp
23.070
USD
+1.76%
EAT
Brinker International Inc
151.610
USD
+2.00%
FAF
First American Financial Corp
60.940
USD
+1.31%
AMKR
Amkor Technology Inc
19.730
USD
-0.95%
ZK
Zeekr Intelligent Technology Holding Ltd
29.340
USD
+1.45%
CELH
Celsius Holdings Inc
39.390
USD
+0.87%
FAQ
Is Kirby Corp (KEX) currently overvalued or undervalued?
Kirby Corp (KEX) is now in the Fair zone, suggesting that its current forward PE ratio of 16.16 is considered Fairly compared with the five-year average of 28.11. The fair price of Kirby Corp (KEX) is between 63.26 to 286.31 according to relative valuation methord.
What is Kirby Corp (KEX) fair value?
How does KEX's valuation metrics compare to the industry average?
What is the current P/B ratio for Kirby Corp (KEX) as of May 18 2025?
What is the current FCF Yield for Kirby Corp (KEX) as of May 18 2025?
What is the current Forward P/E ratio for Kirby Corp (KEX) as of May 18 2025?